Joseph Marszalek, Ph.D.
Stories this photo appears in:
MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
Pre-clinical results for IACS-10759 drug leads to Phase I clinical trials in AML and solid tumors; two papers published in Nature Medicine
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells’ growth and survival.